Projects per year
Personal profile
Personal profile
Dr. Qing Yi is a trained medical immunologist with over 25 years of experience as a well-funded and published researcher. He is one of the leading investigators in the fields of tumor immunology and immunotherapy in multiple myeloma and other cancers.
Since arriving in the US in 1998, Dr. Yi has been awarded, as the PI, 9 R01s from NCI, 1 project and 1 core grant in the MDACC Myeloma SPORE (P50), 4 R01-type translational grants from the LLS, 4 Senior Researcher Awards from the MMRF, 2 K99/R00 grants (as the mentor), and numerous intramural and industry grants. Dr. Yi and colleagues have published more than 160 peer-reviewed research articles, with 45 being in top-tier journals with an impact factor of greater than 10.
Prior to his current appointment as Associate Director of the Houston Methodist Cancer Center, Dr. Yi had faculty appointments at Lerner Research Institute at the Cleveland Clinic in Ohio, MD Anderson Cancer Center, University of Arkansas for Medical Sciences, and Karolinska Hospital and Institute, Sweden.
Research interests
For the past two decades, Dr. Yi's laboratory has been working on the following research:
(1) characterizing myeloma- and tumor-specific T cells and their subsets and examining their functions in relationship to myeloma tumor cells using both in vitro and in vivo approaches
(2) identifying novel myeloma-associated antigens and better methods for immunotherapy
(3) investigating the cross-talk between the tumor microenvironment and the immune system in malignancy
(4) clinical trials to evaluate the efficacy of immunizing patients with idiotype or dendritic cell-based vaccines
(5) exploring immunotherapies using novel myeloma antigens such as DKK1 in multiple myeloma. Our recent research focuses on (a) developing novel therapeutic monoclonal antibodies for myeloma and other cancers, (b) identifying T-cell subsets that have potent anti-tumor effects after adoptive transfer, and (c) identifying tumor microenvironment components that induce tumor drug resistance.
A commentary written by Dr. Edgar Schmitt and Dr. Tobias Bopp in J Clin Invest (122:3857-3859) comments that “During the last two decades the laboratory of Qing Yi has significantly contributed to our current understanding of potential immunotherapies in human malignancies by describing the role of DCs – and particular T cells – in multiple myeloma.”
Education/Academic qualification
Molecular Medicine, Postdoctoral Fellowship, Department of Medicine at the Center for Molecular Medicine (CMM), Karolinska Institutet
1993 → 1995
Medical Sciences, PhD, Doctorate in Medical Sciences (DrMedSci) or Ph.D., Karolinska Institutet
1990 → 1993
Medicine, MB MMed, Master of Medicine (MMed), Sun Yat-Sen University
1983 → 1986
Medicine, MD, Bachelor of Medicine or M.D., Jiangxi Medical College, Jiangxi, P.R. China
1978 → 1983
External positions
Professor of Cancer Biology in Medicine, Weill Cornell Medical College
Oct 1 2019 → …
Research Area Keywords
- Cancer
Free-text keywords
- Hematological malignancies
- Cancer biology
- Cancer immunotherapy
- Myeloma
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
-
Exploring the role and potential of anti-viral drugs to sensitize cancer cells to chemotherapy
6/1/24 → 5/31/29
Project: Federal Funding Agencies
-
Validating Novel Biologic Mediators and Therapeutic Targets in t(4;14) Myeloma
4/1/24 → 4/1/27
Project: Non Profit
-
Combination Therapy Using ATRA and Carfilzomib to Treat Proteasome Inhibitor Refractory Multiple Myeloma
3/1/24 → 2/28/28
Project: State
-
Tumor-specific CD8+ Tc9 cells activate host CD4+ T cells to control antigen-lost tumors
1/1/24 → 12/31/28
Project: Federal Funding Agencies
-
A guideline on the molecular ecosystem regulating ferroptosis
Dai, E., Chen, X., Linkermann, A., Jiang, X., Kang, R., Kagan, V. E., Bayir, H., Yang, W. S., Garcia-Saez, A. J., Ioannou, M. S., Janowitz, T., Ran, Q., Gu, W., Gan, B., Krysko, D. V., Zhu, X., Wang, J., Krautwald, S., Toyokuni, S., Xie, Y., & 28 others , Sep 2024, In: Nature Cell Biology. 26, 9, p. 1447-1457 11 p.Research output: Contribution to journal › Review article › peer-review
39 Scopus citations -
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
Sun, F., Cheng, Y., Wanchai, V., Guo, W., Mery, D., Xu, H., Gai, D., Siegel, E., Bailey, C., Ashby, C., Al Hadidi, S., Schinke, C., Thanendrarajan, S., Ma, Y., Yi, Q., Orlowski, R. Z., Zangari, M., van Rhee, F., Janz, S., Bishop, G., & 3 others , Jan 19 2024, In: Nature Communications. 15, 1, p. 615 615.Research output: Contribution to journal › Article › peer-review
Open Access8 Scopus citations -
Development of therapeutic monoclonal antibodies against DKK1 peptide-HLA-A2 complex to treat human cancers
Qian, J., Wang, Q., Xiao, L., Xiong, W., Xian, M., Su, P., Yang, M., Zhang, C., Li, Y., Zhong, L., Ganguly, S., Zu, Y. & Yi, Q., Jan 24 2024, In: Journal for immunotherapy of cancer. 12, 1, e008145.Research output: Contribution to journal › Article › peer-review
Open Access -
Erratum: Th9 Cells Represent a Unique Subset of CD4+ T Cells Endowed with the Ability to Eradicate Advanced Tumors (Cancer Cell (2018) 33(6) (1048–1060.e7), (S1535610818302186), (10.1016/j.ccell.2018.05.004))
Lu, Y., Wang, Q., Xue, G., Bi, E., Ma, X., Wang, A., Qian, J., Dong, C. & Yi, Q., Jul 8 2024, In: Cancer Cell. 42, 7, p. 1313-1314 2 p.Research output: Contribution to journal › Comment/debate › peer-review
-
Leukocyte immunoglobulin-like receptor B1 (LILRB1) protects human multiple myeloma cells from ferroptosis by maintaining cholesterol homeostasis
Xian, M., Wang, Q., Xiao, L., Zhong, L., Xiong, W., Ye, L., Su, P., Zhang, C., Li, Y., Orlowski, R. Z., Zhan, F., Ganguly, S., Zu, Y., Qian, J. & Yi, Q., Dec 2024, In: Nature Communications. 15, 1, 5767.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations